(EGRX) WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has agreed to appoint Abhinav “Abi” Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders and serve on the Board’s Compensation Committee and Nominating and Corporate Governance Committee. In connection with Mr. Jain’s planned appointment, Eagle entered into a cooperation agreement (the “Agreement”) with Nantahala Capital Management, LLC (together with its affiliates, “Nantahala”), a holder of approximately 38% of the Company’s outstanding shares. Pursuant to the Agreement, Eagle has also agreed to appoint a second new independent director to the Board of Directors no later than May 15, 2026.
Related Questions
How will the appointment of Abhinav Jain and the added board seat influence Eagle Pharmaceuticals' corporate governance and investor confidence?
What are the potential effects of the cooperation agreement with Nantahala Capital Management, which holds ~38% of shares, on the company's control dynamics and future financing needs?
How might the commitment to appoint an additional independent director by May 15, 2026 impact the board composition and strategic direction, and could this trigger any short‑term stock price volatility?